Cargando…
Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: implications for dendritic cell vaccines
Autores principales: | Santana-Magal, Nadine, Farhat-Younis, Leen, Carmi, Yaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351601/ https://www.ncbi.nlm.nih.gov/pubmed/34381569 http://dx.doi.org/10.18632/oncotarget.27972 |
Ejemplares similares
-
T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
por: Rasoulouniriana, Diana, et al.
Publicado: (2023) -
How imiquimod licenses plasmacytoid dendritic cells to kill tumors
por: Holcmann, Martin, et al.
Publicado: (2012) -
In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas
por: Bell, Diana, et al.
Publicado: (1999) -
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA
por: Rastogi, Ichwaku, et al.
Publicado: (2023) -
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy
por: Gutwillig, Amit, et al.
Publicado: (2022)